Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population - PubMed (original) (raw)
Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population
R Y Dodd et al. Transfusion. 2002 Aug.
Abstract
Background: There has been continuing progress in measures to reduce the risk of transfusion-transmitted infection, including introduction of serologic tests of increased sensitivity and the recent implementation of investigational NAT in small pools of samples.
Study design and methods: Data relating to all blood donations to the American Red Cross have been consolidated into a single database. The prevalence of confirmed-positive test results for HBsAg, HCV, HIV, and HTLV were evaluated for each year for first-time donors from 1995 through 2001. Incidence rates for these infections were evaluated among repeat donors having at least two donations in a 2-year period. The frequencies of HIV-1 RNA- and HCV RNA-positive, seronegative donations were assessed for first-time and repeat donations. The relationship risk = (window period) x (incidence) was used to assess residual risk among repeat donations and to evaluate the incidence of HCV and HIV infection among first-time donors.
Results: During the study period, prevalence rates for all markers declined significantly over time: in 2001, the rates per 100,000 were 75.6 for HBsAg, 299 for HCV, 9.7 for HIV, and 9.6 for HTLV; the corresponding incidence rates (/100,000 person-years) were 1.267, 1.889, 1.554, and 0.239, respectively. Estimates of residual risk in donations from repeat donors (after NAT) for HCV and HIV were 1 per 1,935,000 and 1 per 2,135,000, respectively. However, incidence rates for these agents are approximately two times greater among first-time donors. For both HCV and HIV, NAT yield was concordant with that predicted by current window-period models.
Conclusion: These data cover about half of all the whole blood collected in the United States. They suggest increasing improvement in transfusion safety and clearly define the benefit of pooled NAT.
Comment in
- International application of the incidence rate/window period model.
Glynn SA, Kleinman SH, Wright DJ, Busch MP; NHLBI Retrovirus Epidemiology Donor Study. Glynn SA, et al. Transfusion. 2002 Aug;42(8):966-72. doi: 10.1046/j.1537-2995.2002.00200.x. Transfusion. 2002. PMID: 12385404 Review. No abstract available.
Similar articles
- Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.
O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. O'Brien SF, et al. Transfusion. 2007 Feb;47(2):316-25. doi: 10.1111/j.1537-2995.2007.01108.x. Transfusion. 2007. PMID: 17302779 - Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS).
Glynn SA, Kleinman SH, Schreiber GB, Busch MP, Wright DJ, Smith JW, Nass CC, Williams AE. Glynn SA, et al. JAMA. 2000 Jul 12;284(2):229-35. doi: 10.1001/jama.284.2.229. JAMA. 2000. PMID: 10889598 - Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ; German Red Cross NAT Study Group. Hourfar MK, et al. Transfusion. 2008 Aug;48(8):1558-66. doi: 10.1111/j.1537-2995.2008.01718.x. Epub 2008 May 6. Transfusion. 2008. PMID: 18466173 - Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.
Zou S, Stramer SL, Dodd RY. Zou S, et al. Transfus Med Rev. 2012 Apr;26(2):119-28. doi: 10.1016/j.tmrv.2011.07.007. Epub 2011 Aug 25. Transfus Med Rev. 2012. PMID: 21871776 Review. - [Controlled viral risks].
Barin F. Barin F. Transfus Clin Biol. 2000 Feb;7(1):24-9. doi: 10.1016/s1246-7820(00)88708-x. Transfus Clin Biol. 2000. PMID: 10730343 Review. French.
Cited by
- Prevalence, incidence, and residual risks for transfusion-transmitted human immunodeficiency virus Types 1 and 2 infection among Chinese blood donors.
Wang J, Liu J, Yao F, Wen G, Li J, Huang Y, Lü Y, Wen X, Wright D, Yu Q, Guo N, Ness P, Shan H; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II) and International Component. Wang J, et al. Transfusion. 2013 Jun;53(6):1240-9. doi: 10.1111/j.1537-2995.2012.03940.x. Epub 2012 Nov 1. Transfusion. 2013. PMID: 23113801 Free PMC article. - Chronic hepatitis C virus (HCV) disease burden and cost in the United States.
Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Razavi H, et al. Hepatology. 2013 Jun;57(6):2164-70. doi: 10.1002/hep.26218. Epub 2013 May 6. Hepatology. 2013. PMID: 23280550 Free PMC article. - Why the C-statistic is not informative to evaluate early warning scores and what metrics to use.
Romero-Brufau S, Huddleston JM, Escobar GJ, Liebow M. Romero-Brufau S, et al. Crit Care. 2015 Aug 13;19(1):285. doi: 10.1186/s13054-015-0999-1. Crit Care. 2015. PMID: 26268570 Free PMC article. - Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Allain JP, et al. Transfus Med Rev. 2005 Apr;19(2):110-26. doi: 10.1016/j.tmrv.2004.11.005. Transfus Med Rev. 2005. PMID: 15852240 Free PMC article. Review. - Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved?
Samis AJ. Samis AJ. Crit Care Med. 2008 May;36(5):1655-6. doi: 10.1097/CCM.0b013e318170157b. Crit Care Med. 2008. PMID: 18448925 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical